TSE:4507Pharmaceuticals
Is First-in-Class FDA Approval For XOCOVA PEP Altering The Investment Case For Shionogi (TSE:4507)?
Shionogi announced that the U.S. FDA has approved XOCOVA (ensitrelvir) as the first oral antiviral for post-exposure prophylaxis of COVID-19 in adults and adolescents, supported by Phase 3 SCORPIO-PEP trial data showing meaningful prevention of symptomatic infection.
This authorization gives Shionogi a differentiated presence in the COVID-19 prevention landscape, focusing on household contacts where transmission risk is high.
We’ll now examine how securing first-in-class U.S. approval for...